Fractyl Health, Inc.
An American medical company treating obesity and type 2 diabetes at their root. Its lead procedure, Revita, uses a heat-based endoscopic device to resurface the lining of the small intestine, helping people keep weight off after stopping GLP-1 drugs; its Rejuva platform delivers genes that reprogram insulin-making pancreatic cells. Founded in 2010 as MedCatalyst, the firm took its name from "fractal," echoing the repeating folds inside the intestine, and trades on Nasdaq as "GUTS."
Bought 23.0K
Bought 25.0K
Bought 68.5K
Bought 35.0K
Bought 20.0K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Royan AjayDirector · 1 transaction | +0.4% | 6.45M | — | 23.0K | — |
| Rajagopalan HarithChief Executive Officer, Director · 1 transaction | +3.5% | 1.14M | — | 25.0K | — |
| Bradley WilliamDirector · 1 transaction | +424.7% | 84.6K | — | 68.5K | — |
| Sheffield IanDirector · 1 transaction | — | 35.0K | — | 35.0K | — |
| Smith Weber LaraChief Financial Officer · 1 transaction | — | 20.0K | — | 20.0K | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 6 months: +171.5K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.